Odyssey Health Inc Stock Price, News & Analysis

Odyssey Group International (OTC: ODYY) has successfully developed a novel drug-device combination product aimed at treating concussions, completing its formulation for human clinical trials. The product, which can be administered as a spray-dried powder via the nasal cavity, targets brain swelling and oxidative stress post-concussion. Certified by Upperton Limited, the product is prepared for Phase 1 trials. Executive VP Jacob VanLandingham emphasized increased drug efficacy with reduced side effects. The company aims to make significant advancements in medical solutions while addressing substantial market opportunities.

Odyssey Group International, Inc. (OTC: ODYY) recently featured on the show 'Banfield' to discuss their concussion treatment, PRV-002. Key figures from the Sports Advisory Board, including NFL legends Brett Favre, Kurt Warner, and Mark Rypien, highlighted the urgent need for effective concussion therapies. PRV-002, a synthetic neurosteroid, demonstrated strong preclinical results by improving neuroprotective effects and reducing brain injury symptoms. Odyssey aims to raise public awareness about concussions and plans to seek FDA approval for PRV-002.

Odyssey Group International, Inc. (OTC: ODYY) announced the successful completion of IND-enabling studies and the submission of their Investigator’s Brochure for Ethics Committee review to initiate Phase 1 clinical trials for a concussion treatment. This is a significant progression towards addressing a major medical need. The studies confirmed PRV-002's safety and efficacy, with expectations that the Ethics Committee will finalize its review this month. CEO Michael Redmond expressed confidence in PRV-002's safety and stability as they prepare for human trials.

Odyssey Group International has announced that its VP of Drug Development, Jake VanLandingham, along with NFL legends Brett Favre, Kurt Warner, and Mark Rypien, will appear on Banfield on July 27, 2021, at 10:00 pm ET.

They will discuss the urgent need for a treatment for concussion, highlighting PRV-002, a neurosteroid candidate. Recent studies indicate that 15% of individuals with concussions face long-term health issues. The Murdoch Children's Research Institute reported that 1/3 of youth who sustain concussions develop mental health issues, underscoring the need for effective therapies.

Odyssey Group International, Inc. (OTCQB: ODYY) announced it will hold its Annual Meeting of Stockholders in September 2021. Stockholder proposals must be submitted by August 5, 2021, to be considered. The company focuses on developing life-saving medical products and aims to acquire distinct assets and technologies for medical solutions. A Notice of Annual Meeting and Proxy Statement will be filed with the SEC after reviewing stockholder proposals. Forward-looking statements highlight potential risks and uncertainties affecting future performance.

Odyssey Group International (OTCQB: ODYY) announced the successful completion of final safety studies and cellular safety assays for its drug PRV-002, aimed at treating concussions. With a favorable review indicating no significant cardiac risk or mutagenesis, the drug is set for a final safety evaluation by the Clinical Trial Ethics Committee before human trials begin. The nasal applicator device met quality control standards, showing no contamination. PRV-002 has shown promising preclinical results, indicating potential neuroprotective effects and ability to address brain injury symptoms.

Odyssey Group International, Inc. (OTCQB: ODYY) announced that CEO Michael Redmond and Executive VP Dr. Jake VanLandingham will present at the 2021 LD Micro Invitational XI Investor Conference. The presentation is scheduled for June 10, 2020, from 11:00-11:30 am EDT. They will discuss the company's strategy for developing and acquiring life-saving medical products, including drug candidate PRV-002, aimed at treating concussions. Odyssey's mission focuses on creating distinct assets and technologies that enhance medical solutions.

Odyssey Group International (OTCQB: ODYY) announced the completion of a novel nano-particle drug formulation designed to enhance brain distribution of PRV-002, aimed at treating concussions. This formulation, paired with a proprietary nasal device, is expected to improve drug delivery directly to the brain, reducing systemic exposure and side effects. Clinical trials are set to begin this summer. The drug has shown promising neuroprotective effects in preclinical studies, with potential benefits in reducing oxidative stress and inflammation.

Odyssey Group International (OTCQB: ODYY) announced a significant milestone in developing its concussion drug, PRV-002. The completion of FDA-required toxicology studies has set the stage for a Phase 1 clinical trial, contracted with Nucleus Network in Australia. Preclinical studies suggest PRV-002 has a safety margin over 100-fold the intended dosing, preparing the company for clinical trials this summer. The data will support their Investigational New Drug Application (IND) with the FDA, paving the way for future Phase 2 trials in the US.